Endocr Pract. 2019 Aug;25(8):787-793. doi: 10.4158/EP-2018-0607. Epub 2019 Apr 23.
The aim of this study was to investigate the prognostic value of metabolic characteristics of metastatic lymph node (LN) using pretreatment F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for patients with papillary thyroid carcinoma (PTC) and metastatic lateral LN (N1b). Ninety-six PTC patients (female:male = 72:24; median age, 44.5 years) with pathologic N1b who underwent pretreatment FDG PET/CT, total thyroidectomy, and radioactive iodine ablation were retrospectively reviewed. To predict responses to initial therapy and recurrence, clinicopathologic factors and metabolic parameters were reviewed, such as sex, age, tumor size, extranodal extension, number and ratio of metastatic LNs, serum thyroglobulin, and maximum standardized uptake value (SUVmax). Among the 96 PTC patients, 81 (84.4%) were classified into the acceptable response (58 excellent; 23 indeterminate) and 15 (15.6%) into the incomplete response (8 biochemical incomplete; 7 structural incomplete) by the 2015 American Thyroid Association management guideline for differentiated thyroid carcinoma. The multivariate analysis showed that SUVmax of N1b ( = .018), pre-ablation stimulated thyroglobulin level ( = .006), and the ratio of metastatic LNs ( = .018) were related to incomplete response. The cutoff value of each variable was determined by receiver operating characteristic analysis. Nine (9.4%) patients experienced recurrences (median follow-up: 50 months). The Kaplan-Meier analysis revealed that SUVmax of N1b (cutoff value: 2.3; = .025) and ratio of metastatic LNs (cutoff value: 0.218; = .037) were significant prognostic factors for recurrence. High SUVmax of N1b cervical LN on pretreatment FDG PET/CT could predict incomplete responses to initial therapy and recurrence in patients with N1b PTC. = American Thyroid Association; = well-differentiated thyroid carcinoma; = F-18 fluorodeoxyglucose; = interquartile range; = lymph node; = metastatic lateral cervical lymph node; = positron emission tomography/computed tomography; = papillary thyroid carcinoma; = radioactive iodine; = receiver operating characteristic; = maximum standardized uptake value; = thyroglobulin; = ultrasonography.
本研究旨在探讨使用术前 F-18 氟脱氧葡萄糖(FDG)正电子发射断层扫描/计算机断层扫描(PET/CT)评估甲状腺乳头状癌(PTC)伴转移性侧颈部淋巴结(N1b)患者的转移性淋巴结(LN)代谢特征的预后价值。 回顾性分析了 96 例经术前 FDG PET/CT、全甲状腺切除术和放射性碘消融治疗的 PTC 患者(女:男=72:24;中位年龄 44.5 岁),其中病理 N1b。 为了预测初始治疗和复发的反应,回顾了临床病理因素和代谢参数,如性别、年龄、肿瘤大小、淋巴结外侵犯、转移性淋巴结的数量和比例、血清甲状腺球蛋白和最大标准化摄取值(SUVmax)。 在 96 例 PTC 患者中,根据 2015 年美国甲状腺协会分化型甲状腺癌管理指南,81 例(84.4%)被归类为可接受的反应(58 例为完全缓解;23 例为不确定),15 例(15.6%)为不完全反应(8 例为生化不完全;7 例为结构不完全)。 多因素分析显示,N1b 的 SUVmax( =.018)、消融前刺激甲状腺球蛋白水平( =.006)和转移性淋巴结的比例( =.018)与不完全反应相关。 通过受试者工作特征分析确定了每个变量的截断值。 9 例(9.4%)患者出现复发(中位随访时间:50 个月)。 Kaplan-Meier 分析显示,N1b 的 SUVmax(截断值:2.3; =.025)和转移性淋巴结比例(截断值:0.218; =.037)是预测复发的显著预后因素。 术前 FDG PET/CT 中 N1b 颈淋巴结的高 SUVmax 可预测 N1b PTC 患者对初始治疗的不完全反应和复发。